Released Aug 8, 2023, before the open
10-Q filed Aug 8, 2023, 39 days after period end · 0001171843-23-005113
Q2 2023 · 10-Q
Revenue$28.76M$28.76M −1.5% vs Q2 2022−4.1% vs Q1 2023
Net Income-$980.00K-$980.00K N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.02-$0.02 N/M vs Q2 2022N/M vs Q1 2023
Gross Profit$16,673,000+0.2%
Operating Income$796,000−80.1%
Operating Cash Flowderived$3,552,000N/M
Free Cash Flowderived$3,035,000N/M
Margins · derived
Gross margin58.0%+1.0 pt vs Q2 2022
Operating margin2.8%−10.9 pt vs Q2 2022
Net margin-3.4%−11.7 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $28.76M | $29.21M | $29.20M | $23.31M |
| Net Income | -$980.00K | $2.44M | -$410.00K | -$1.58M |
| EPS Diluted | -$0.02 | $0.06 | -$0.01 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR